Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
Abstract Background Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Previous studies in PAH have demonstrated greater treatment benefits in m...
Main Authors: | R. James White, Anton Vonk-Noordegraaf, Stephan Rosenkranz, Ronald J. Oudiz, Vallerie V. McLaughlin, Marius M. Hoeper, Ekkehard Grünig, Hossein-Ardeschir Ghofrani, Murali M. Chakinala, Joan A. Barberà, Christiana Blair, Jonathan Langley, Adaani E. Frost |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-09-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-019-1180-1 |
Similar Items
-
Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
by: Gérald Simonneau, et al.
Published: (2020-12-01) -
IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension
by: Hunter Gillies, et al.
Published: (2024-01-01) -
Medical management of chronic thromboembolic pulmonary hypertension
by: Joanna Pepke-Zaba, et al.
Published: (2017-03-01) -
Future perspectives in pulmonary arterial hypertension
by: Gérald Simonneau, et al.
Published: (2016-12-01) -
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study
by: Hunter Gillies, et al.
Published: (2023-03-01)